NCT03990896: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a somatic (NOT hereditary) BRCA 1 or 2 mutation that is detectable by cell-free circulating tumor DNA (including but not restricted to MGH-Snapshot cfDNA assay, Guardant360, Foundation One)
Exclusions: Patients who have not received prior platinum based chemotherapy; Patients who progressed while on platinum treatment or within 6 months after end of treatment; Patients who received prior treatment with a PARP inhibitor; Patients with symptomatic, unstable, untreated brain or leptomeningeal metastases- see trial for details; Patients with a germline (hereditary) BRCA mutation

Comments are closed.

Up ↑